Human-growth hormone injection-related Creutzfeldt-Jakob Disease (Q92020): Difference between revisions
From determinar.ia.br - Determine suas informações
Changed an Item |
Changed an Item |
||||||||||||||
| (One intermediate revision by the same user not shown) | |||||||||||||||
| Property / Knowledge Architect | |||||||||||||||
| Property / Knowledge Architect: https://pauloleads.com.br/cases-publicos/ / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / Collection date | |||||||||||||||
15 August 2026
| |||||||||||||||
| Property / Collection date: 15 August 2026 / rank | |||||||||||||||
Normal rank | |||||||||||||||
Latest revision as of 07:10, 16 August 2026
Human growth hormone-related Creutzfeldt-Jakob Disease (CJD) is CJD in patients treated with human growth hormone derived from the pituitary glands in the brains of cadaveric donors. The clinical features include progressive cerebellar ataxia and a longer disease course than classical sCJD. After the prohibition of the cadaveric use for growth hormone, the occurrence of CJD in this manner has been drastically reduced.
| Language | Label | Description | Also known as |
|---|---|---|---|
| default for all languages | ID_866329807 |
||
| English | Human-growth hormone injection-related Creutzfeldt-Jakob Disease |
Human growth hormone-related Creutzfeldt-Jakob Disease (CJD) is CJD in patients treated with human growth hormone derived from the pituitary glands in the brains of cadaveric donors. The clinical features include progressive cerebellar ataxia and a longer disease course than classical sCJD. After the prohibition of the cadaveric use for growth hormone, the occurrence of CJD in this manner has been drastically reduced. |
Statements
CID11:ID_866329807
0 references
dki-india-ID_866329807
0 references
Concluído
0 references
15 August 2026
0 references
